Skip to main content
. 2020 Dec 4;12(12):3630. doi: 10.3390/cancers12123630

Figure 1.

Figure 1

In vitro PLK1 knockdown by RGD-LNP in human endothelial cells expressing integrin. (A) Representative histograms based on flow cytometric analysis for LEC and HUVEC stained with the control antibody or anti-integrin antibody. (B) Representative histograms based on flow cytometric analysis of the uptake of PEG-LNP or RGD-LNP labeled with DiO in LEC or HUVEC. (C) Cellular uptake of PEG-LNP or RGD-LNP labeled with DiO in LEC or HUVEC measured using flow cytometric analysis. Data are shown as the mean ± S.E. (n = 3). * p < 0.05. (D) Expression of PKL1 in HUVEC after treatment with PEG-LNP at 100 nM or RGD-LNP at indicated concentrations of siPLK1 for 24 h. Data are shown as the mean ± S.E. (n = 3). N.T.: No treatment.